Neprilysin-Like Protease-gamma, Mouse (NEPL-g), Control Peptide

A 15-aa peptide sequence mapping at the extracellular domain (within the unique 37-aa insert) of mouse NEPL-g.\n\nThe amyloid beta-peptide (Ab) of 39 to 43aa (Ab40, Ab42, Ab43) is constitutively produced in brain upon proteolysis of the b-amyloid precursor protein (APP). In the young and healthy humans, Ab is rapidly catabolized before it can be deposited in the brain. However, upon aging or the onset of familial Alzheimer's Disease, alterations in either synthesis or degradation/clearance of Ab may contribute to amyloid depositions in the brain. Ab is susceptible to a number of in vivo and in vitro proteases like cathepsin-D and M-13 metalloproteases. The M-13 family includes several members of zinc-dependent proteases like damage-induced neuronal endopeptidase (DINE), product of phosphate regulating gene with homologies to endopeptidases on the X chromosome (PHEX), neutral endopeptidase 24.11 or neprilysin (NEP) and neprilysin-like proteases (NEPLs). NEPLs (alpha, -beta, gamma) arise from the alternative splicing of a single NELPS gene and show ~54% sequence homology. M13 members are generally type II transmembrane proteins consisting of a single polypeptide chain with Zinc binding HEXXH motif, a short cytoplasmic tail, a transmembrane segment and an extra-cytoplasmic domain containing the enzyme active site.\n\nNEPL-g is a 115kD (779 aa) with a Zinc binding HEXXH motif in its extracellular domain. NEPL-g appears to have a different conformation and substrate specificity than those of NEPL-a. In comparison to NEPL-a, NEPL-g has an additional sequence of 37aa (311-347) near the center of the polypeptide which possibly inhibits its activity by interfering with proper folding and interaction with the substrate. Unlike NEP, NEPL-g has no proteolytic activity to either synthetic or Ab peptides and does not appear to be a possible in vivo peptidase for endogenous Ab. Proteolytic activation of endopeptidase activity of NEPL-g by a partial/complete removal of the unique region (311-347aa) in its sequence has been proposed.\n\nApplications:\nSuitable for use in ELISA and Antibody Blocking. Because of its low MW (<3kD), not suitable for Western Blot. Other applications not tested.\n\nRecommended Dilutions: \nELISA: 50-100ng/well\nAntibody Blocking: 5-10ug per 1ug of N2030-60 (purified IgG) or 1ul of N2030-55 (antiserum).\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. For long-term storage, aliquot and store at -20 degrees C. Aliquots are stable for at least 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.\n

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

N2030-58

Size

50ug

Applications

ELISA, WB

Form

Supplied as a liquid in PBS, pH 7.5

Purity

Highly purified

References

1. Shirotani K et al (2001) JBC 276, 21895-21901 2. Iwata et al. (2001) Science 292, 1550 3. Ikeda et al. (1999) J. Biol. Chem. 274, 32469 4. Boileau et al. (2001) Biochem. J 355, 107 5. Kiryu-Seo et al. (2000) PNAS 97, 4345.

Additional Info

The antigenic/control peptide is conserved in mouse (100%) NEPL-g. No significant sequence homology of is seen with other proteins. The control peptide, because of its low MW (<3kD), is not suitable for Western